EGLN1 and cancer: Pathways in cancer had the largest number of Pathways in cancer have the largest number of anti-cancer/tumor-associated targets, including EGLN1, GSK3B, MMP1, MMP2, PRKCA, MMP9, EGFR, MAPK10, AR, CASP7, CASP8, CASP3, and MAPK1.